Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies

Comprehensive molecular portraits of human breast tumours

The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Gianni, L., Pieńkowski, T., Im, Y., Roman, L., Tseng, L., Liu, M.-C., Lluch, A. M., Starosławska, E., de la Haba-Rodríguez, J., Im, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70336-9 · Cited by 2,427

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer

Prat, A., Parker, J. S., Karginova, O. A., Fan, C., Livasy, C., Herschkowitz, J. I., He, X., & Perou, C. M. (2010) · Breast Cancer Research · doi:10.1186/bcr2635 · Cited by 2,290

Generation of a functional mammary gland from a single stem cell

Shackleton, M., Vaillant, F., Simpson, K. J., Stingl, J., Smyth, G. K., Asselin-Labat, M.-L., Wu, L., Lindeman, G. J., & Visvader, J. E. (2006) · Nature · doi:10.1038/nature04372 · Cited by 2,005

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627

Molecular Definition of Breast Tumor Heterogeneity

Shipitsin, M. V., Campbell, L. L., Argani, P., Weremowicz, S., Bloushtain-Qimron, N., Yao, J., Nikolskaya, T., Serebryiskaya, T., Beroukhim, R., Hu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.01.013 · Cited by 1,347

Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors

Herschkowitz, J. I., Simin, K. J., Weigman, V., Mikaelian, I., Usary, J., Hu, Z., Rasmussen, K., Jones, L. P., Assefnia, S., Chandrasekharan, S., et al. (2007) · Genome biology · doi:10.1186/gb-2007-8-5-r76 · Cited by 1,337

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

Baselga, J. M., Bradbury, I., Eidtmann, H., Cosimo, S. D., de Azambuja, E., Aura, C. M., Gómez, H., Dinh, P., Fauria, K., Dooren, V. V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61847-3 · Cited by 1,324

Hedgehog Signaling and Bmi-1 Regulate Self-renewal of Normal and Malignant Human Mammary Stem Cells

Liu, S., Dontu, G., Mantle, I. D., Patel, S. H., Ahn, N.-S., Jackson, K. W., Suri, P., & Wicha, M. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0054 · Cited by 1,241

The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer

Cataldo, M. L., Placido, P. D., Esposito, D., Formisano, L., Arpino, G., Giuliano, M., Bianco, R., Angelis, C. D., & Veneziani, B. M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1108242 · Cited by 19

Conditional generative adversarial network driven radiomic prediction of mutation status based on magnetic resonance imaging of breast cancer

Huang, Z. H., Chen, L., Sun, Y., Liu, Q., & Hu, P. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05018-9 · Cited by 22

Kinome-wide screening of HER2+ breast cancer cells for molecules that mediate cell proliferation or sensitize cells to trastuzumab therapy

Lapin, V., Shirdel, E. A., Wei, X., Mason, J. M., Jurišica, I., & Mak, T. W. (2014) · Oncogenesis · doi:10.1038/oncsis.2014.45 · Cited by 19

Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment

Castel, P., Toska, E., Zumsteg, Z. S., Carmona, F. J., Elkabets, M., Bosch, A., & Scaltriti, M. (2014) · Molecular & Cellular Oncology · doi:10.4161/23723548.2014.963447 · Cited by 22

Organismal roles for the PI3Kα and β isoforms: their specificity, redundancy or cooperation is context-dependent.

Arcucci, S., Ramos-Delgado, F., Cayron, C., Therville, N., Gratacap, M., Basset, C., Thibault, B., & Guillermet-Guibert, J. (2021) · Biochemical Journal · doi:10.1042/bcj20210004 · Cited by 15

Detailed curriculum vitae of HER2-targeted therapy

Zhang, X., Gao, Y., Zhang, X.-Y., Guo, N.-J., Hou, W., Wang, S.-W., Zheng, Y., Wang, N., Liu, H., & Wang, B. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108417 · Cited by 19

Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic

Fabi, A., Mottolese, M., & Segatto, O. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1169-7 · Cited by 18

Monitoring Trastuzumab Resistance and Cardiotoxicity

Dokmanovic, M., & Wu, W. J. (2015) · Advances in clinical chemistry · doi:10.1016/bs.acc.2015.03.006 · Cited by 18

Lentiviral Vector-based Insertional Mutagenesis Identifies Genes Involved in the Resistance to Targeted Anticancer Therapies

Ranzani, M., Annunziato, S., Calabria, A., Brasca, S., Benedicenti, F., Gallina, P., Naldini, L., & Montini, E. (2014) · Molecular Therapy · doi:10.1038/mt.2014.174 · Cited by 17

Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice

Bu, W., Creighton, C. J., Heavener, K. S., Gutiérrez, C., Dou, Y., Ku, A. T., Zhang, Y., Jiang, W., Urrutia, J. M., Jiang, W., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade0059 · Cited by 20

Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA H1047R in HER2/ER-positive breast cancer

Cheng, F., Zhao, J., Hanker, A. B., Brewer, M. R., Arteaga, C. L., & Zhao, Z. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-4011-9 · Cited by 16

Human HER2 overexpressing mouse breast cancer cell lines derived from MMTV.f.HuHER2 mice: characterization and use in a model of metastatic breast cancer

Park, S., Nedrow, J. R., Josefsson, A., & Sgouros, G. (2017) · Oncotarget · doi:10.18632/oncotarget.19174 · Cited by 16

Molecular alterations and poziotinib efficacy, a pan‐HER inhibitor, in human epidermal growth factor receptor 2 (HER2)‐positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2‐positive breast cancer patients

Kim, J., Lee, E., Park, K., Jung, H. H., Park, W., Lee, K., Sohn, J., Lee, K. S., Jung, K. H., Kim, J. H., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32188 · Cited by 16

Preclinical Comparison of [ 111 In]In- and [ 225 Ac]Ac-DOTA-Trastuzumab IgG, F(ab′) 2 and Fab for Theranostic SPECT/CT Imaging and α-Particle Radioimmunotherapy of HER2-Positive Human Breast Cancer

Kondo, M., Cai, Z., Chan, C., Brown, M. K., & Reilly, R. M. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c01071 · Cited by 16

Syngeneic mouse model of human HER2+ metastatic breast cancer for the evaluation of trastuzumab emtansine combined with oncolytic rhabdovirus

Taha, Z., Crupi, M. J. F., Alluqmani, N., Fareez, F., Ng, K., Sobh, J., Lee, E., Chen, A., Thomson, M., Spinelli, M. M., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1181014 · Cited by 14

Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer

Cai, A., Chen, Y., Wang, L. S., Cusick, J., & Shi, Y. H. (2024) · Cancers · doi:10.3390/cancers16152635 · Cited by 15

A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations

Blair, B. G., Wu, X., Zahari, M. S., Mohseni, M., Cidado, J. R., Wong, H. Y., Beaver, J. A., Cochran, R. L., Zabransky, D. J., Croessmann, S., et al. (2014) · PROTEOMICS · doi:10.1002/pmic.201400342 · Cited by 14

Targeting the Pro-survival Protein BCL-2 to Prevent Breast Cancer

Young, A. I. J., Bu, W., Jiang, W., Ku, A., Kapali, J., Dhamne, S., Qin, L., Hilsenbeck, S. G., Du, Y.-C. N., & Li, Y. (2021) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-21-0031 · Cited by 14

Specific HER2 Exon 20 Gly776 Deletion-Insertions in Non-Small Cell Lung Cancer: Structural Analysis and Sensitivity to HER2-Targeted Tyrosine Kinase Inhibitors

Yang, G., Xu, H., Hu, J., Liu, R., Hu, P., Yang, Y., Li, W., Hao, X., Zhang, S., Xu, F., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.806737 · Cited by 13

Generation and Characterization of Trastuzumab/Pertuzumab-Resistant HER2-Positive Breast Cancer Cell Lines

Sanz-Álvarez, M., Luque, M., Morales-Gallego, M., Cristóbal, I., Ramírez-Merino, N., Rangel, Y., Izarzugaza, Y., Eroles, P., Albanell, J., Madoz‐Gúrpide, J., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010207 · Cited by 13

The PI3K/AKT/MTOR Signaling Pathway: The Role of PI3K and AKT Inhibitors in Breast Cancer

Huemer, F., Bartsch, R., & Gnant, M. (2014) · Current Breast Cancer Reports · doi:10.1007/s12609-014-0139-y · Cited by 13

Overview of Genetically Engineered Mouse Models of Breast Cancer Used in Translational Biology and Drug Development

Greenow, K. R., & Smalley, M. J. (2015) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph1436s70 · Cited by 13

Use of a genetically engineered mouse model as a preclinical tool for HER2 breast cancer

Creedon, H., Balderstone, L. A., Muir, M., Balla, J., Gómez-Cuadrado, L., Tracey, N., Loane, J. F., Klinowska, T. C. M., Muller, W. J., & Brunton, V. G. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.023143 · Cited by 13

Oncogenic PIK3CA corrupts growth factor signaling specificity

Madsen, R. R., Marois, A. L., Mruk, O. N., Voliotis, M., Yin, S., Sufi, J., Qin, X., Zhao, S. J., Górczyńska, J., Morelli, D., et al. (2024) · Molecular Systems Biology · doi:10.1038/s44320-024-00078-x · Cited by 13

Inhibiting ERK5 Overcomes Breast Cancer Resistance to Anti-HER2 Therapy By Targeting the G1–S Cell-Cycle Transition

Zhang, J., Pearson, A. J., Sabherwal, N., Telfer, B. A., Ali, N., Kan, K., Xu, Q., Zhang, W., Chen, F., Li, S.-Y., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-21-0089 · Cited by 11

The intricate interplay between cancer stem cells and cell-of-origin of cancer: implications for therapeutic strategies

Bamodu, O. A., Chung, C., Pisanic, T. R., & Wu, A. T. H. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1404628 · Cited by 13

Plasma PIK3CA ctDNA specific mutation detected by next generation sequencing is associated with clinical outcome in advanced breast cancer.

Li, H., Xu, Y., Zhao, F., Song, G., Rugo, H. S., Zhang, Y., Yang, L., Liu, X., Shao, B., Yang, L., et al. (2018) · Europe PMC (PubMed Central) · Cited by 11

A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer

Bertho, M., Patsouris, A., Augereau, P., Robert, M., Frenel, J., Blonz, C., & Campone, M. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1844662 · Cited by 11

Genomic alterations associated with HER2+ breast cancer risk and clinical outcome in response to trastuzumab

Singla, H., Kaur, R. P., Shafi, G., Vashistha, R., Banipal, R. P. S., Kumar, V., & Munshi, A. (2018) · Molecular Biology Reports · doi:10.1007/s11033-018-4537-5 · Cited by 11

The clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population: a FOCUS study analysis

Engels, C. C., Kiderlen, M., Bastiaannet, E., van Eijk, R., Mooyaart, A. L., Smit, V. T. H. B. M., de Craen, A. J. M., Kuppen, P. J. K., Kroep, J. R., van de Velde, C. J. �., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3734-y · Cited by 11

Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer

Grinshpun, A., Ren, S., Graham, N., DeMeo, M. K., Wrabel, E., Carter, J., Tayob, N., Pereslete, A., Hamilton, E., Juric, D., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103465 · Cited by 10

Deciphering the Role of Phosphatidylinositol 3-Kinase Mutations in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Goel, S., & Krop, I. E. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0742 · Cited by 10

Insertional mutagenesis in a HER2-positive breast cancer model reveals ERAS as a driver of cancer and therapy resistance

Ikink, G. J., Boer, M., Bakker, E. R. M., Vendel-Zwaagstra, A., Klijn, C., ten Hoeve, J., Jonkers, J., Wessels, L. F. A., & Hilkens, J. (2018) · Oncogene · doi:10.1038/s41388-017-0031-0 · Cited by 10

Using Phosphatidylinositol Phosphorylation as Markers for Hyperglycemic Related Breast Cancer

Devanathan, N., Jones, S. R., Kaur, G., & Kimble-Hill, A. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072320 · Cited by 12

Familial CCM Genes Might Not Be Main Drivers for Pathogenesis of Sporadic CCMs-Genetic Similarity between Cancers and Vascular Malformations

Zhang, J., Croft, J., & Le, A. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13040673 · Cited by 11

Aspirin Treatment Effect and Association with PIK3CA Mutation in Breast Cancer: A Biomarker Analysis

Zhou, Y., Simmons, J. D., Jordan, C. D., Sonbol, M. B., Maihle, N. J., & Tang, S. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.05.004 · Cited by 10

Inhibiting the PI3K signaling pathway: buparlisib as a new targeted option in breast carcinoma

García‐Estévez, L., García, E. G., & Hidalgo, M. M. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1410-z · Cited by 10

An update on promising and emerging protein kinase B/AKT inhibitors for breast cancer

Asnaghi, R., Antonarelli, G., Battaiotto, E., Castellano, G., Guidi, L., Izzo, D., Zagami, P., Trapani, D., & Curigliano, G. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2454290 · Cited by 10

MUC1 triggers lineage plasticity of Her2 positive mammary tumors

Pang, Z., Dong, X., Deng, H., Wang, C., Liao, X., Liao, C., Liao, Y., Tian, W., Cheng, J., Chen, G., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02320-y · Cited by 9

Heregulin–ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells

Yarar, D., Lahdenranta, J., Kubasek, W., Nielsen, U. B., & MacBeath, G. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0075 · Cited by 9

The H1047R PIK3CA oncogene induces a senescence-like state, pleiotropy and acute HSP90 dependency in HER2+ mammary epithelial cells

Chakrabarty, A., Surendran, S., Bhola, N. E., Mishra, V. S., Wani, T. H., Baghel, K. S., Arteaga, C. L., Garg, R., & Chowdhury, G. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz118 · Cited by 9

Molecular dissection of PI3Kβ synergistic activation by receptor tyrosine kinases, GβGγ, and Rho-family GTPases

Duewell, B. R., Wilson, N. E., Bailey, G. M., Peabody, S. E., & Hansen, S. D. (2024) · eLife · doi:10.7554/elife.88991 · Cited by 9

Involvement of the AKT Pathway in Resistance to Erlotinib and Cabozantinib in Triple-Negative Breast Cancer Cell Lines

Lefebvre, C., Pellizzari, S., Bhat, V., Jurčić, K., Litchfield, D. W., & Allan, A. L. (2023) · Biomedicines · doi:10.3390/biomedicines11092406 · Cited by 9

Clinical Implications of Mutations in the PI3K Pathway in HER2+ Breast Cancer: Prognostic or Predictive?

Mayer, I. A. (2015) · Current Breast Cancer Reports · doi:10.1007/s12609-015-0197-9 · Cited by 8

Defining the Prognostic and Predictive Role of PIK3CA Mutations: Sifting Through the Conflicting Data

Al‐Sukhun, S., Lataifeh, I. M., & Al-Sukhun, R. (2016) · Current Breast Cancer Reports · doi:10.1007/s12609-016-0215-6 · Cited by 8

Remarkable Response of EGFR- and HER2-Amplified Metastatic Colon Cancer to Pyrotinib After Failed Multiline Treatments: A Case Report and Literature Review

Li, H., Yang, L., Zhang, M., Cheng, K., Chen, Y., & Liu, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.548867 · Cited by 8

Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis

Yamamoto, Y., Iwata, H., Saji, S., Takahashi, M., Yoshinami, T., Ueno, T., Toyama, T., Yamanaka, T., Takano, T., Kashiwaba, M., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-01673 · Cited by 6

Fc-mediated immune stimulating, pro-inflammatory and antitumor effects of anti-HER2 IgE against HER2-expressing and trastuzumab-resistant tumors

Grandits, M., Palhares, L. C. G. F., Osborn, G., Chauhan, J., Stoker, K., Sow, H. S., Adams, R., McCraw, A. J., Chenoweth, A. M., Vlasova, S., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010945 · Cited by 6

Dual Blockade of HER-2 Provides a Greater Magnitude of Benefit in Patients With Hormone-Negative Versus Hormone-Positive Breast Cancer

Abramovitz, M., Williams, C. B., Loibl, S., & Leyland-Jones, B. R. (2016) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.06.004 · Cited by 6

Direct Inhibition of PI3K in Combination with Dual HER2 Inhibitors is Required for Optimal Antitumor Activity in HER2+ Breast Cancer Cells

Rexer, B. N., Chanthaphaychith, S., Dahlman, K. B., & Arteaga, C. L. (2014) · Apple Academic Press eBooks · doi:10.1201/b17138-4 · Cited by 6

Chip-based digital Polymerase Chain Reaction as quantitative technique for the detection of PIK3CA mutations in breast cancer patients

Giannoni‐Luza, S., Acosta, Ó., Carrasco, A. G. M., Danos-Diaz, P., Cotrina, J. M., Miller, H. G., Pinto, J. A., Aguilar, A., Araujo, J. M., Fujita, R., et al. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e11396 · Cited by 5

Cooperative oncogenic effect and cell signaling crosstalk of co-occurring HER2 and mutant PIK3CA in mammary epithelial cells

Dong, L., Meng, F., Wu, L., Mitchell, A. V., Block, C. J., Zhang, B., Craig, D. B., Jang, H., Chen, W., Yang, Q., et al. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4108 · Cited by 5

HER2 Signaling Network in Advanced Breast Cancer: Opportunities for Combination Therapies

Dey, N., Leyland-Jones, B. R., & De, P. K. (2016) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-34211-5_8 · Cited by 4

Trastuzumab in combination with paclitaxel enhances antitumor activity by promoting apoptosis in human epidermal growth factor receptor 2-positive trastuzumab-resistant gastric cancer xenograft models

Shu, S., Yamashita‐Kashima, Y., Yanagisawa, M., Nakanishi, H., Kodera, Y., Harada, N., & Yoshimura, Y. (2019) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000853 · Cited by 4

A tipping-point for apoptosis following dual inhibition of HER2 signaling network by T-DM1 plus GDC-0980 maximizes anti-tumor efficacy.

Dey, N., Aske, J. C., Lin, X., Sun, Y., Leyland-Jones, B. R., Friedman, L. S., & De, P. K. (2021) · PubMed Central · Cited by 4

Characterization of HER2-Positive Murine Breast Cancer Models for Investigating HER2-Targeted Therapy and Immunotherapy

Lu, Y., Lee, B. P., Eli, A. V., Lynch, S. E., Faisal, A.-R. M., Moye, J. A., & Sorace, A. G. (2026) · Cancers · doi:10.3390/cancers18060997 · Cited by 3

Chemotherapeutic Activity of Imidazolium-Supported Pd(II) o-Vanillylidene Diaminocyclohexane Complexes Immobilized in Nanolipid as Inhibitors for HER2/neu and FGFR2/FGF2 Axis Overexpression in Breast Cancer Cells

Awaji, A. A., Rizk, M. A., Alsaiari, R. A., Alqahtani, N. F., Al-Qadri, F. A., Alkorbi, A. S., Hafez, H. S., & Elshaarawy, R. F. M. (2023) · Pharmaceuticals · doi:10.3390/ph16121711 · Cited by 3

PIK3CA rs7640662 (C/G) single nucleotide polymorphism lacks association with breast cancer cases in Persians

Mir, A., Sadegh, M., Ahmadinia, Z., & Kaboli, P. J. (2015) · Interventional Medicine and Applied Science · doi:10.1556/imas.7.2015.1.1 · Cited by 3

Resistance to HER2-Targeted Therapy

Theile, D., Lenz, G., Momand, J. A., & Kane, S. E. (2017) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-70142-4_2 · Cited by 3

Deep targeted sequencing analysis of hot spot mutations in non-small cell lung cancer patients from the Middle Eastern population

Khoueiry, P., Fakhri, G. B., Akel, R., Assaad, M. A., Mahfouz, R. A., Khuri, F. R., Chami, H. A., Petersen, J. L., Viet, S., Davies, G., et al. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.05.74 · Cited by 3

Molecular dissection of PI3Kβ synergistic activation by receptor tyrosine kinases, GβGγ, and Rho-family GTPases

Duewell, B. R., Wilson, N. E., Bailey, G. M., Peabody, S. E., & Hansen, S. D. (2024) · eLife · doi:10.7554/elife.88991.3 · Cited by 2

Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast Cancers

Heeke, A. L., Elliott, A., O'Keefe, K., Livasy, C., Symanowski, J. T., Steiner, M. R., Kang, I. M., Hoon, D. S. �., Walker, P., Sledge, G. W., et al. (2025) · JCO Precision Oncology · doi:10.1200/po.23.00719 · Cited by 4

Hyperprogressive disease induced by PD-1 inhibitor monotherapy in lung adenocarcinoma with HER2 exon 20 insertion: report of two cases and review of literature

Yang, G., Tian, L., & Wang, Y. (2025) · Discover Oncology · doi:10.1007/s12672-025-01749-3 · Cited by 2

Personalized Therapies for Cancer Treatment

Nair, L., & Gonzalez-Angulo, A. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-416603-5.00013-4 · Cited by 2

Heterogeneous clinical and pathological landscapes of HER2 positive colorectal cancer

Chen, Z., Chen, J., Gao, Y., & Quan, M. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1944108 · Cited by 2

Transcriptomically-inferred PI3K activity and stemness show a counterintuitive correlation with PIK3CA genotype in breast cancerPreprint

Madsen, R. R., Rueda, O. M., Robin, X., Caldas, C., Semple, R. K., & Vanhaesebroeck, B. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.09.195974 · Cited by 2

Oncogenic PIK3CA corrupts growth factor signaling specificityPreprint

Madsen, R. R., Marois, A. L., Mruk, O. N., Voliotis, M., Yin, S., Sufi, J., Qin, X., Zhao, S. J., Górczyńska, J., Morelli, D., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.23.573207 · Cited by 2

Trastuzumab and pertuzumab plus carboplatin-based neoadjuvant therapy for HER2-positive breast cancer: a prospective cohort study with integrated genomic and transcriptomic biomarker analysis

Qian, X., Chen, X., Xiao, M., Ji, L., Li, Q., Wang, J., Fan, Y., Luo, Y., Cai, R., Lan, B., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251403929 · Cited by 1

New Directions in the Neoadjuvant Treatment of HER2+ Breast Cancer

Hobbs, E. A., & Hurvitz, S. A. (2015) · Breast Cancer Management · doi:10.2217/bmt.15.12 · Cited by 1

Next-Generation Sequencing Based Testing for Breast Cancer

Ganesan, S., & Hirshfield, K. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-41761-5_20 · Cited by 1

Molecular dissection of PI3Kβ synergistic activation by receptor tyrosine kinases, GβGγ, and Rho-family GTPasesPreprint

Duewell, B. R., Wilson, N. E., Bailey, G. M., Peabody, S. E., & Hansen, S. D. (2023) · eLife · doi:10.7554/elife.88991.1 · Cited by 1

Genetically engineered mouse models of breast carcinoma: a translational resource for highlighting human breast subtype etiology and developing personalized therapeutic approaches

Pfefferle, A. D. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/6bg2-dy11

Basic Research

Maru, Y. (2016) · Springer eBooks · doi:10.1007/978-4-431-56024-1_10

Basic Research

Maru, Y. (2021) · Springer eBooks · doi:10.1007/978-981-16-1757-7_10

Alpelisib-induced acute cholestatic hepatitis in a patient with metastatic breast cancer- a case report

Ashraf, A., Daloya, J., Barnes, M., Ansari, U., Ashraf, N., Lee, H., & Caruso, R. (2022) · Current Problems in Cancer Case Reports · doi:10.1016/j.cpccr.2022.100200

Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistancePreprint

Cheng, X., Sun, Y., Highkin, M. K., Vemalapally, N., Jin, X., Zhou, B., Prior, J. L., Tipton, A. R., Li, S., Iliuk, A. B., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.09.515796

Supplementary Tables S1-S5 from Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations

Dogruluk, T., Tsang, Y. H., Espitia, M., Chen, F., Chen, T., Chong, Z., Appadurai, V., Dogruluk, A., Eterovic, K. A., Bonnen, P. E., et al. (2023) · doi:10.1158/0008-5472.22406975

Supplementary Tables S1-S5 from Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations

Dogruluk, T., Tsang, Y. H., Espitia, M., Chen, F., Chen, T., Chong, Z., Appadurai, V., Dogruluk, A., Eterovic, K. A., Bonnen, P. E., et al. (2023) · doi:10.1158/0008-5472.22406975.v1

Figure S1 from Inhibiting ERK5 Overcomes Breast Cancer Resistance to Anti-HER2 Therapy By Targeting the G1–S Cell-Cycle Transition

Zhang, J., Pearson, A. J., Sabherwal, N., Telfer, B. A., Ali, N., Kan, K., Xu, Q., Zhang, W., Chen, F., Li, S.-Y., et al. (2023) · doi:10.1158/2767-9764.22544312.v1

Data from Targeting the Pro-survival Protein BCL-2 to Prevent Breast Cancer

Young, A. I. J., Bu, W., Jiang, W., Ku, A. T., Kapali, J., Dhamne, S., Qin, L. F., Hilsenbeck, S. G., Du, Y. N., & Li, Y. (2023) · doi:10.1158/1940-6207.c.6547696.v1

Data from Precision Combination Therapies Based on Recurrent Oncogenic Coalterations

Li, X., Dowling, E. K., Yan, G., Dereli, Z., Bozorgui, B., Imanirad, P., Elnaggar, J. H., Luna, A., Menter, D. G., Pilie, P. G., et al. (2023) · doi:10.1158/2159-8290.c.6549560.v1

Data from Inhibiting ERK5 Overcomes Breast Cancer Resistance to Anti-HER2 Therapy By Targeting the G1–S Cell-Cycle Transition

Zhang, J., Pearson, A. J., Sabherwal, N., Telfer, B. A., Ali, N., Kan, K., Xu, Q., Zhang, W., Chen, F., Li, S.-Y., et al. (2023) · doi:10.1158/2767-9764.c.6550601.v1

Supplementary Table from Precision Combination Therapies Based on Recurrent Oncogenic Coalterations

Li, X., Dowling, E. K., Yan, G., Dereli, Z., Bozorgui, B., Imanirad, P., Elnaggar, J. H., Luna, A., Menter, D. G., Pilie, P. G., et al. (2023) · doi:10.1158/2159-8290.22541159.v1

Molecular dissection of PI3Kβ synergistic activation by receptor tyrosine kinases, GβGγ, and Rho-family GTPases

Duewell, B. R., Wilson, N. E., Bailey, G. M., Peabody, S. E., & Hansen, S. D. (2023) · doi:10.1101/2023.05.01.538969

Molecular dissection of PI3Kβ synergistic activation by receptor tyrosine kinases, GβGγ, and Rho-family GTPasesPreprint

Duewell, B. R., Wilson, N. E., Bailey, G. M., Peabody, S. E., & Hansen, S. D. (2024) · eLife · doi:10.7554/elife.88991.2

Multi-gradient permutation survival analysis identifies mitosis and immune signatures steadily associated with cancer patient prognosis

Cai, X., Ye, Y., Liu, X., Fang, Z., Chen, L., Li, F., & Ji, H. (2025) · eLife · doi:10.7554/elife.101619.3

Additional file 2 of Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA

Garay, J. P., Smith, R. L., Devlin, K. L., Hollern, D. P., Liby, T. A., Liu, M., Boddapati, S. P., Watson, S. S., Esch, A. M., Zheng, T., et al. (2021) · Figshare · doi:10.6084/m9.figshare.15102847

Clinical implications of resistance to anti-HER2 antibodies in breast cancer

Dhanisha, S. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-816408-2.00005-1

Multi-gradient permutation survival analysis identifies mitosis and immune signatures steadily associated with cancer patient prognosisPreprint

Cai, X., Ye, Y., Liu, X., Fang, Z., Chen, L., Li, F., & Ji, H. (2024) · eLife · doi:10.7554/elife.101619

Multi-gradient Permutation Survival Analysis Identifies Mitosis and Immune Signatures Steadily Associated with Cancer Patient PrognosisPreprint

Cai, X., Ye, Y., Liu, X., Fang, Z., Chen, L., Li, F., & Ji, H. (2024) · eLife · doi:10.7554/elife.101619.1

Multi-gradient Permutation Survival Analysis Identifies Mitosis and Immune Signatures Steadily Associated with Cancer Patient PrognosisPreprint

Cai, X., Ye, Y., Liu, X., Fang, Z., Chen, L., Li, F., & Ji, H. (2025) · eLife · doi:10.7554/elife.101619.2

Additional file 1 of Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA

Garay, J. P., Smith, R., Devlin, K. L., Hollern, D. P., Liby, T., Liu, M., Boddapati, S. P., Watson, S. S., Esch, A. M., Zheng, T., et al. (2021) · Figshare · doi:10.6084/m9.figshare.15102844

Additional file 1 of Evaluating the immunologically “cold” tumor microenvironment after treatment with immune checkpoint inhibitors utilizing PET imaging of CD4 + and CD8 + T cells in breast cancer mouse models

Lü, Y., Houson, H. A., Gallegos, C., Mascioni, A., Jia, F., Aivazian, A., Song, P. N., Lynch, S. E., Napier, T. S., Mansur, A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26103786

Lung Metastasis of HER2-positive Breast Cancer with Squamous Cell Differentiation Phenotype: A Case Report

Qiu, Y., & Lu, Y. (2025) · American Journal of Clinical and Experimental Medicine · doi:10.11648/j.ajcem.20251306.12

Exploring PI3K signalling dynamics in pancreatic cancer

Delgado, C. F. R. (2020) · theses.fr (ABES) · doi:10.70675/6df9a059zc3f1z4997z9de2z34a1d24dfbeb

Interaction of therapeutic antibodies with heme : functional repercussions and prediction of developability issues

Kanyavuz, A. (2022) · doi:10.70675/45f8ab45zab05z478dzb41azaf4496ced5ac

Impact of somatic PIK3CA mutations on clinical outcomes in HER2-positive breast cancer

Stabellini, N., de Oliveira, S. D., Mizukami, T., Sweeney, S. M., Schultz, N., Kehl, K. L., Riely, G., Panageas, K., Schrag, D., Bedard, P. L., et al. (2026) · Breast Cancer Research · doi:10.1186/s13058-026-02324-6

Aspirin enhances the anti-tumour activity of lapatinib in HER2-positive breast cancer

Luo, H., Yuan, P., Guo, K., Chen, J., Xu, J., Jiang, Y., Wang, C., Liu, J., Wang, B., & Zhu, X. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179132

PI3K/AKT signaling pathway: molecular crossroads in tumorigenesis and therapeutic innovation

Shi, Q., Liu, J., Chu, Q., Zeng, Y., Zhang, Y., Jiang, S., Yuan, X., Zhu, D., & Li, L. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02770-w · Cited by 1

Abstract A007: Mutant PIK3CA accelerates HER2-driven transgenic mammary tumor progression, enhances cancer stem cell features, and induces resistance to combinations of anti-HER2 therapies

Hanker, A. B., Pfefferle, A. D., Balko, J. M., Kuba, M. G., Young, C. D., Sanchez, V. M., Sutton, C. R., Cheng, H.-L. M., Perou, C. M., Zhao, J. J., et al. (2013) · Molecular Cancer Research · doi:10.1158/1557-3125.advbc-a007

Abstract 4875: Human HER2 and PI3K H1047R cooperate to promote mammary tumorigenesis in vivo

Hanker, A. B., Kuba, M. G., Sanchez, V. M., Sutton, C. R., Pfefferle, A. D., Balko, J. M., Perou, C. M., Cook, R. S., & Arteaga, C. L. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-4875 · Cited by 50

Abstract 1822: HER2/PIK3CAH1047R transgenic tumors develop acquired resistance to triple therapy with trastuzumab, pertuzumab, and PI3K inhibitors via multiple mechanisms

Hanker, A. B., Young, C. D., Stricker, T. P., Cook, R. S., & Arteaga, C. L. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-1822

Abstract PD5-8: HER2/PIK3CAH1047R transgenic mammary tumors develop acquired resistance to triple therapy with trastuzumab, pertuzumab and PI3K inhibitors via multiple mechanisms

Hanker, A. B., Bulen, B., Brewer, M. R., Young, C. D., Farrar, K. M., Cook, R. S., Stricker, T. P., & Arteaga, C. L. (2015) · Cancer Research · doi:10.1158/1538-7445.sabcs14-pd5-8

PIK3CAH1047R and Her2 initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling

Cheng, H.-L., Liu, P.-X., Ohlson, C. E., Xu, E., Symonds, L., Isabella, A., Muller, W., Lin, N., Krop, I., Roberts, T., et al. (2015) · Oncogene · doi:10.1038/onc.2015.377 · Cited by 40